Zobrazeno 1 - 3 of 3 pro vyhledávání: '"Marina V. Kosinova"'
1
Akademický článek
The efficacy and safety of eculizumab biosimilar in patients with paroxysmal nocturnal hemoglobinuria. Results of a phase III randomized open-label comparative clinical trial
Autor: Aleksandr D. Kulagin, Bulat A. Bakirov, Igor L. Davydkin, Ilya V. Elykomov, Tatiana S. Konstantinova, Aleksandr V. Korobkin, Marina V. Kosinova, Vadim I. Mazurov, Natalia V. Minaeva, Andrei V. Proidakov, Vadim V. Ptushkin, Yuri V. Shatokhin, Yulia N. Lin'kova, Arina V. Zinkina-Orikhan, Maria A. Morozova
Publikováno v: Терапевтический архив, Vol 93, Iss 11, Pp 1340-1348 (2021)
Aim. To establish the equivalent efficacy and comparable safety profile of biosimilar Acveris and referent eculizumab product Soliris used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Materials and methods. Were included in the
Externí odkaz: https://doaj.org/article/0d5384bfdbda43c5bcf66f68f5f0d5ac
Zobrazit plný text záznamu
2
Akademický článek
Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
Autor: Johnny Mahlangu, Howard Levy, Marina V. Kosinova, Heghine Khachatryan, Bartosz Korczowski, Levani Makhaldiani, Genadi Iosava, Martin Lee, Frank Del Greco
Publikováno v: Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 6, Pp n/a-n/a (2021)
Abstract Background Marzeptacog alfa (activated) (MarzAA), a novel recombinant activated human factor VII (FVIIa) variant, was developed to provide increased procoagulant activity, subcutaneous (SC) administration, and longer duration of action in pe
Externí odkaz: https://doaj.org/article/a9322a7798624e72884c4f60d04eb1af
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje